# EDGAR Filing Document

**Accession Number:** 0001082554
**File Stem:** 0001673232-25-000012
**Filing Date:** 2025-11
**Character Count:** 7490
**Document Hash:** 118f51f6e1bada873e803fedc22ce1b5
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001673232-25-000012.hdr.sgml**: 20251118

**ACCESSION NUMBER**: 0001673232-25-000012

**CONFORMED SUBMISSION TYPE**: 4

**PUBLIC DOCUMENT COUNT**: 1

**CONFORMED PERIOD OF REPORT**: 20251117

**FILED AS OF DATE**: 20251118

**DATE AS OF CHANGE**: 20251118

**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** BENKOWITZ MICHAEL
- **CENTRAL INDEX KEY:** 0001673232

**ORGANIZATION NAME:**

**FILING VALUES:**
- **FORM TYPE:** 4
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 000-26301
- **FILM NUMBER:** 251495307

**MAIL ADDRESS:**
- **STREET 1:** C/O UNITED THERAPEUTICS CORP
- **STREET 2:** 1040 SPRING STREET
- **CITY:** SILVER SPRING
- **STATE:** MD
- **ZIP:** 20910
**ISSUER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** UNITED THERAPEUTICS Corp
- **CENTRAL INDEX KEY:** 0001082554
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 521984749
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**BUSINESS ADDRESS:**
- **STREET 1:** 1000 SPRING ST
- **CITY:** SILVER SPRING
- **STATE:** MD
- **ZIP:** 20910
- **BUSINESS PHONE:** 3016089292

**MAIL ADDRESS:**
- **STREET 1:** 1000 SPRING ST
- **CITY:** SILVER SPRING
- **STATE:** MD
- **ZIP:** 20910

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** UNITED THERAPEUTICS CORP
- **DATE OF NAME CHANGE:** 19990324

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 4

### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

[x] Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>BENKOWITZ MICHAEL<br><sub>(Last) (First) (Middle)</sub><br>C/O UNITED THERAPEUTICS CORPORATION<br>1000 SPRING STREET<br><sub>(Street)</sub><br>SILVER SPRING, MD 20910<br><sub>(City) (State) (Zip)</sub> | **3. Date of Earliest Transaction (Month/Day/Year)**<br>2025-11-17 | **5. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[ ] Director [ ] 10% Owner<br>[X] Officer (give title below) [ ] Other (specify below)<br>_PRESIDENT AND COO_ |
| **2. Issuer Name and Ticker or Trading Symbol**<br>UNITED THERAPEUTICS Corp [ UTHR ] | **4. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[X] Form filed by One Reporting Person<br>[ ] Form filed by More than One Reporting Person |

---

## Table I - Non-Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | 3. Transaction Code (V) | 3. Transaction Code (V) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | Code | V | Amount | (A) or (D) | Price | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| Common Stock | 2025-11-17 |  | M<sup>(1)</sup> |  | 14625.00 | A | $135.42 | 14625.00 | I | by Trust<sup>(2)</sup> |
| Common Stock | 2025-11-17 |  | S<sup>(1)</sup> |  | 14625.00 | D | $470.4336 | 0.00 | I | by Trust<sup>(2)</sup> |
| Common Stock | 2025-11-17 |  | M<sup>(1)</sup> |  | 2625.00 | A | $146.03 | 2625.00 | I | by Trust<sup>(3)</sup> |
| Common Stock | 2025-11-17 |  | M<sup>(1)</sup> |  | 5250.00 | A | $146.03 | 7875.00 | I | by Trust<sup>(3)</sup> |
| Common Stock | 2025-11-17 |  | S<sup>(1)</sup> |  | 7875.00 | D | $470.4336 | 0.00 | I | by Trust<sup>(3)</sup> |
| Common Stock |  |  |  |  |  |  |  | 2648.00 | D |  |

---

## Table II - Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | 4. Transaction Code (V) | 4. Transaction Code (V) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 6. Date Exercisable and Expiration Date | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Underlying Securities | 7. Title and Amount of Underlying Securities | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| Stock Options | $135.42 | 2025-11-17 |  | M<sup>(1)</sup> |  |  | 14625.00 | 2023-03-15 | 2026-03-15 | Common Stock | 14625.00 | $0.00 | 12000.00 | I | by Trust<sup>(2)</sup> |
| Stock Options | $146.03 | 2025-11-17 |  | M<sup>(1)</sup> |  |  | 2625.00 | 2023-03-15 | 2026-03-15 | Common Stock | 2625.00 | $0.00 | 0.00 | I | by Trust<sup>(3)</sup> |
| Stock Options | $146.03 | 2025-11-17 |  | M<sup>(1)</sup> |  |  | 5250.00 | 2023-03-15 | 2026-03-15 | Common Stock | 5250.00 | $0.00 | 37690.00 | I | by Trust<sup>(3)</sup> |

---

### Footnotes:

(1) This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on August 7, 2024.

(2) Reflects the exercise of options, and sale of the resulting shares of common stock, held in a trust beneficially owned by the Reporting Person, of which the Reporting Person is a beneficiary, and as to which the Reporting Person and his spouse are co-trustees and haveshared investment and voting power.

(3) Reflects the exercise of options, and sale of the resulting shares of common stock, held in a trust beneficially owned by the Reporting Person, of which the Reporting Person's family members are beneficiaries, and as to which the Reporting Person has sole investment and voting power.

**Signature:** /s/ John S. Hess, Jr. under Power of Attorney  
**Date:** 2025-11-18

### Remarks:

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**